




APPROVED	O.G. FIG.	
	CLASS	SUBCLASS
BY		
DRAFTSMAN		

FIG. 1

Average Proteinuria Grade
Combined SLE Experiments
+/- SEM



No Therapy/Vehicle..... n = 40 - 129 per timepoint
Anti-B7.1 + anti-B7.2 (each 200ug, 3x/wk, 2 wks)..... n = 8 - 47 per timepoint

- No Treatment
- anti-B7.1 + anti-B7.2



APPROVED BY DRAFTSMAN	O.G. FIG.	CLASS	SUBCLASS

Dosing Protocol

SLE-5 Treatment, 3x/wk, Subcutaneously		Age (weeks)																	
		25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40		
A	5 mg/kg Rapamycin (AY-22989-21)	→																	
B	200 ug/ms anti-murine B7.1	→																	
	200 ug/ms anti-murine B7.2	→																	
C	5 mg/kg Rapamycin (AY-22989-21)	→																	
	200 ug/ms anti-murine B7.1	→																	
	200 ug/ms anti-murine B7.2	→																	
D	5 mg/kg Rapamycin (AY-22989-21)																		
E	5 mg/kg Rapamycin (AY-22989-21)	→																	
	200 ug/ms anti-murine B7.1	→																	
	200 ug/ms anti-murine B7.2	→																	
F	200 ug/ms anti-murine IL-12	→																	
G	Vehicle	→																	

FIGURE 2



APPROVED	O.G. FIG.	CLASS	SUBCLASS
	BY	DRAFTSMAN	


97 JPS-002 SLE-7 Histopathologic Evaluation of NZB x NZW F1 Hybrid Female Mice							
42 weeks of age							
Group	Animal	Spleen	Spleen	Kidney	Kidney	Kidney	
No Therapy		Lymphoid Hyperplasia	Hematopoiesis	Interstitial Inflammation	Glomerulonephritis	Cellularity- Membrane Thickness	Tubular Dilatation
	1	-2	-3	+2	-2	+2	+3
	2	+2	+2	+3	-1	+3	+3
	3	+2	+2	+2	-1	+3	+2
	4	+2	+2	+3	-3	+3	+4
	5	+2	+3	+3	-3	+3	+4
	Mean	+1.2	+1.2	+2.6	-2.0	+2.8	+3.2
Rapamycin (Treatment Weeks 29-36)							
	1	+1	+1	(+1)	0	+1	+1
	2	+1	+1	(+1)	0	+1	0
	3	+1	+1	(+2)	0	0	0
	4	+1	+1	0	0	0	0
	5	+1	+1	(+1)	0	0	0
	Mean	+1.0	+1.0	+1.0	0	+0.4	+0.2
<div>Histologic Grades</div> <div> 0 = Normal 1 = Slight 2 = Mild 3 = Moderate 4 = Marked 5 = Severe () = Focal not Diffuse </div>							
Histopathologic Assessment : Elizabeth Goad, PhD, DVM.							

FIGURE 3




APPROVED	O.G. FIG.	
	CLASS	SUBCLASS
BY	DRAFTSMAN	

FIG. 4A



- (A) Early Rapa (C) Anti-B7s + Early Rapa (E) Anti-B7s + Late Rapa
 (B) Anti-B7s (D) Late Rapa (F) Anti-IL-12
 (G) No Therapy

FIG. 4B



- (A) Early Rapa (C) Anti-B7s + Early Rapa (E) Anti-B7s + Late Rapa
 (B) Anti-B7s (D) Late Rapa (F) Anti-IL-12
 (G) No Therapy



A.

Single Therapeutic Dosing




FIGURE 5A

B.

Combined Therapeutic Dosing




FIGURE 5B